Meibei Biotechnology Launches Microencapsulated Herbal Joint Care Line with 40% Higher Bioavailability

Meibei Biotechnology Launches Microencapsulated Herbal Joint Care Line with 40% Higher Bioavailability

Luoyang Meibei Biotechnology Co., Ltd., backed by the R&D platform of the National Veterinary Drug Engineering Technology Research Center, has officially launched its new generation of herbal pet joint care product line.

Engineered for canine and feline joint degeneration, the line adopts microencapsulation technology and low-temperature cold-pressed extraction. It fully complies with EU and North American pet supplement regulations, and is now available for global OEM/ODM customization services.

The core formula combines astragalus, curcumin, chondroitin and other active ingredients. The three-layer microcapsule structure protects active compounds from gastric acid and oxidation, enabling targeted release in the intestinal tract. Laboratory data shows nutrient bioavailability is over 40% higher than traditional powder products, while herbal odors are effectively masked for better palatability. The product range includes softgels, chewable tablets and powders, with customizable formula strength, dosage form and packaging.

Manufactured in dust-free GMP workshops, every batch undergoes triple testing for heavy metals, microbiology and active ingredient content. Complete export documents including COA, Certificate of Origin and Sanitary Certificate are provided, with multi-language label support to meet FEDIAF and AAFCO standards.

With a flexible supply chain, the line supports low MOQ trial orders with sample delivery in as fast as 7 days, catering to brands, retail chains and veterinary clinics of all sizes. Free samples are available upon request for global partners.